Peptides
Find every peptide in the research library. Each page shows its available local studies or identifies the evidence missing from the packet.
Start with an outcome instead →
30 peptides
How strong is the evidence?
Grades describe certainty for a specific outcome. See how we grade.
Questions & answers
Questions from public discussions, answered with research.
Does BPC-157 speed tendon or ligament healing?
The knee-pain case series measured subjective symptoms, without objective confirmation of tendon or ligament repair.[1] In a 2026 rat Achilles-repair experiment, BPC-157 alone did not significantly improve maximum load to failure versus control.[2] That experiment used four tendons per group for each endpoint, so its nonsignificant result does not establish that no effect exists.[2] Pain relief and tissue repair are different outcomes: a report of less pain does not show that a torn tendon has regained its structure or mechanical strength.[1] The rat experiment assessed surgically repaired Achilles tendons, so it also cannot determine whether BPC-157 accelerates recovery from the range of tendon injuries seen in clinical practice.[2]
Study context and limitations
- Population
- Knee-pain patients and surgically injured rats.[1][2]
- Study design
- Human case series indirect for structural repair; exploratory rat repair experiment.[1][2]
- Outcome
- Structural tendon or ligament healing.[1][2]
- Formulation / route
- Study-specific; no cross-route equivalence assumed.[1][2]
- Key limitation
- Symptoms and preclinical endpoints do not establish human structural repair.[1][2]
What does the human knee-pain study show?
Of seventeen patients identified, sixteen were contacted; eleven of twelve receiving BPC-157 alone reported improvement.[1] The uncontrolled, retrospective design and subjective outcomes cannot separate a drug effect from recovery, expectation or other care.[1] The patients had different types of knee pain, and the study did not include a comparable group receiving placebo or usual care alone.[1] The finding is therefore a preliminary signal of reported symptom improvement, rather than evidence that BPC-157 treats a defined knee disorder or repairs damaged cartilage.[1]
Study context and limitations
What evidence supports muscle-injury recovery?
Rat experiments reported improved muscle-to-bone reattachment and recovery after muscle–tendon junction separation.[3][4] A separate rat muscle-crush experiment reported improved healing during corticosteroid exposure.[5] These induced injuries support further research but do not establish human recovery times, effective doses or safe drug combinations.[3][4][5] The experiments address different injuries and treatment conditions, making their results specific to those models rather than a single, established effect on muscle recovery.[3][4][5] They do not answer whether an athlete or a patient undergoing rehabilitation would regain strength sooner, return to activity earlier, or experience fewer complications.[3][4][5]
Study context and limitations
- Population
- Rats with induced muscle injuries.[3][4][5]
- Study design
- Controlled rat surgical and crush-injury experiments.[3][4][5]
- Outcome
- Muscle recovery in people.[3][4][5]
- Formulation / route
- Study-specific; no cross-route equivalence assumed.[3][4][5]
- Key limitation
- No direct human muscle-recovery trial in these studies.[3][4][5]
Does BPC-157 heal the gut or treat inflammatory bowel disease?
Studies in animals report reduced injury in rat models of gastric ulcers and concentrated-alcohol exposure.[6][7] FDA separately reviewed a small placebo-controlled ulcerative-colitis study reported only as a meeting abstract, with insufficient detail for a reliable effectiveness assessment.[8] Those findings do not establish a benefit for commercial oral BPC-157 products or nonspecific “leaky gut” symptoms.[6][8] Damage caused experimentally by concentrated alcohol is a different research problem from treating chronic inflammatory bowel disease in people.[7] The animal results provide a reason to investigate gastrointestinal effects, but the incomplete human report does not establish which patients would benefit, how large the benefit would be, or whether it would persist.[6][7][8]
Study context and limitations
- Population
- Rat gastric-injury models; separate human ulcerative-colitis abstract.[6][7][8]
- Study design
- Rat injury experiments; regulatory assessment of an abstract-only human trial.[6][7][8]
- Outcome
- Human digestive benefit.[6][7][8]
- Formulation / route
- Study-specific; no cross-route equivalence assumed.[6][7][8]
- Key limitation
- Human evidence includes an incompletely reported meeting abstract, with insufficient detail to assess effectiveness reliably.[6][7][8]